Wednesday, April 03, 2019 9:29:21 AM
ACCESSWIRE ACCESSWIREApril 3, 2019
ANN ARBOR, MI / ACCESSWIRE / April 3, 2019 / ENDRA Life Sciences Inc. (''ENDRA'') (NDRA), a developer of enhanced ultrasound technologies, has received Medical Device Quality Management System ISO 13485:2016 and EN ISO 13485:2016 certification, under Certificate Number MD 697226 from British Standards Institution (BSI). This ISO certification indicates that the company's Quality Management System (QMS) meets the most current regulatory requirements specific to the medical device industry.
The ISO 13485:2016 standard for medical devices establishes the requirements for a comprehensive system, covering the design, manufacture, and distribution of medical devices. ENDRA's ISO 13485:2016 certification scope includes:
Design, development, control of manufacture, service, installation and distribution of thermo-acoustic enhanced ultrasound medical devices and accessories.
This ISO 13485:2016 scope indicates that ENDRA has established the Quality Management System infrastructure necessary for it to complete the design and initiate commercialization of the ENDRA Life Sciences-patented Thermo Acoustic Enhanced Ultrasound (TAEUS) clinical technology, designed to aid clinicians in management of liver disease with fatty tissue characterization (pending product-specific CE-Marking).
''This certification represents an important milestone achievement towards our CE Mark as it demonstrates the commitment of our global cross-functional team to quality, and to meeting customer and international regulatory expectations,'' said Amy Sitzler, ENDRA's Vice President of Engineering and Programs. ''This ISO 13485 certification and scope verifies the Quality Management System designed to ensure the highest quality product development and manufacture of our TAEUS FLIP System. It is the culmination of a year's work of development, implementation, training and refinement of nearly 50 core business processes,'' concluded Sitzler.
The ISO 13485:2016 certification is an internationally recognized standard for the medical device industry. The U.S. Food and Drug Administration (FDA) recently announced its intention to adopt the ISO 13485:2016 standard, in an effort to harmonize the FDA Quality System Regulation, 21 CFR 820, with the international standard.
''A commitment to quality is central to our mission and we believe that achieving the British Standards Institute (BSI) ISO 13485:2016 certification validates our team's capabilities and maturity in establishing ENDRA's processes to develop and manufacture diagnostic products for medical use,'' said ENDRA's CEO Francois Michelon.
About ISO
The International Organization for Standardization (ISO) is the world's largest developer and publisher of international standards for the implementation of quality management systems. The ISO quality management standard embodies the requirements for a comprehensive management system for the design and manufacture of medical devices. ISO is a global network of national standards bodies and its members are the foremost standards organizations in their respective countries. Each member represents its country in ISO. BSI, the United Kingdom's representative, is a full ISO member (member body) that influences ISO standards development and strategy by participating and voting in ISO technical and policy meetings. Full members sell and adopt ISO international standards nationally. For more information, please click here.
About British Standards Institute (BSI)
BSI (British Standards Institution) equips businesses with the necessary solutions to turn standards of best practice into habits of excellence. From assessment, certification and training to software solutions, advisory services and supply chain intelligence, BSI provides the full solution to facilitate business improvement and help clients drive performance, manage risk and grow sustainably. Through the passion and expertise of our people, BSI embeds excellence in organizations across the globe to improve business performance and resilience. BSI's influence spans across multiple sectors with particular focus on Aerospace, Automotive, Built Environment, Food, Retail, Healthcare and IT. For more information, please click here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. ("ENDRA") (NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the fatty liver tissue characterization, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
"The Investors's Chief Problem--and even his worst enemy--is likely to be himself"
---Benjamin Graham
Recent NDRA News
- ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents • Business Wire • 05/02/2024 12:00:00 PM
- ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Business Wire • 03/28/2024 08:05:00 PM
- ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 • Business Wire • 03/21/2024 12:00:00 PM
- ENDRA Life Sciences Installs First TAEUS System in the UK • Business Wire • 02/27/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 10:00:45 PM
- New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System • Business Wire • 02/21/2024 01:00:00 PM
- ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe • Business Wire • 02/14/2024 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/29/2023 10:07:32 PM
- ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology • Business Wire • 11/29/2023 01:00:00 PM
- ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference • Business Wire • 11/27/2023 01:00:00 PM
- ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update • Business Wire • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:02:23 PM
- ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents • Business Wire • 11/08/2023 01:00:00 PM
- ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 • Business Wire • 11/07/2023 09:05:00 PM
- ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023 • Business Wire • 11/06/2023 01:00:00 PM
- Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023 • Business Wire • 09/07/2023 12:00:00 PM
- ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA • Business Wire • 08/30/2023 12:00:00 PM
- ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents • Business Wire • 08/23/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:45:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:13:52 PM
- ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update • Business Wire • 08/14/2023 08:05:00 PM
- ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA • Business Wire • 08/14/2023 05:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:01:23 PM
- ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023 • Business Wire • 08/01/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM